Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Common Equity: 2016-2024

Historic Common Equity for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $262.9 million.

  • Organogenesis Holdings' Common Equity fell 8.41% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 8.41%. This contributed to the annual value of $262.9 million for FY2024, which is 5.66% down from last year.
  • Per Organogenesis Holdings' latest filing, its Common Equity stood at $262.9 million for FY2024, which was down 5.66% from $278.7 million recorded in FY2023.
  • Organogenesis Holdings' Common Equity's 5-year high stood at $278.7 million during FY2023, with a 5-year trough of $141.8 million in FY2020.
  • Moreover, its 3-year median value for Common Equity was $265.7 million (2022), whereas its average is $269.1 million.
  • In the last 5 years, Organogenesis Holdings' Common Equity surged by 155.13% in 2020 and then declined by 5.66% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Common Equity (Yearly) stood at $141.8 million in 2020, then skyrocketed by 70.18% to $241.3 million in 2021, then grew by 10.08% to $265.7 million in 2022, then rose by 4.89% to $278.7 million in 2023, then declined by 5.66% to $262.9 million in 2024.